CGON financial statements
The full income statement, balance sheet, and cash-flow statement for CG Oncology Inc. (CGON), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| Revenue | 4.04M+254.7% | 1.14M+458.3% | 204K | |
| — | 116M+108.1% | 55.7M | ||
| Research & development | 117M+42.1% | 82.1M+79.5% | 45.8M | |
| Selling, general & administrative | 73.5M+118.2% | 33.7M+240.4% | 9.90M | |
| General & administrative | 73.5M+118.2% | 33.7M+240.4% | 9.90M | |
| Operating income | -191M-66.4% | -115M-106.8% | -55.4M | |
| Interest & investment income | 29.9M+12.4% | 26.6M+285.6% | 6.90M | |
| Other non-operating income | -152K-5166.7% | 3.00K+104.8% | -62.0K | |
| Income tax | -270K-27100.0% | 1.00K+0.0% | 1.00K | |
| -161M-82.9% | -88.0M-81.1% | -48.6M | ||
| Net income to common | -161M-82.9% | -88.0M-29.9% | -67.8M | |
| -$2.08-47.5% | -$1.41+91.0% | -$15.65 | ||
| EPS (basic) | -$2.08-47.5% | -$1.41+91.0% | -$15.65 | |
| Weighted-avg shares (basic) | 77.3M+23.7% | 62.5M+1343.0% | 4.33M | |
| Weighted-avg shares (diluted) | 77.3M+23.7% | 62.5M+1343.0% | 4.33M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| 759M+0.7% | 754M+288.5% | 194M | ||
| Cash & equivalents | 32.5M-87.4% | 257M+3009.9% | 8.27M | |
| Short-term investments | 710M+46.3% | 485M+170.3% | 179M | |
| Accounts receivable | 688K | 0.00 | — | |
| Inventory | 1.56M | 0.00 | — | |
| Prepaid expenses | 15.1M+23.4% | 12.2M+92.1% | 6.36M | |
| 792M+4.9% | 755M+278.7% | 199M | ||
| Property, plant & equipment | 15.6M+5633.8% | 272K+294.2% | 69.0K | |
| Operating lease right-of-use | 3.97M+1696.8% | 221K-47.6% | 422K | |
| Goodwill | 10.3M | 0.00 | — | |
| Intangible assets | 575K | 0.00 | — | |
| Other non-current assets | 1.68M+1685.1% | 94.0K+394.7% | 19.0K | |
| 30.8M+44.3% | 21.4M+49.9% | 14.3M | ||
| Accounts payable | 5.71M-12.3% | 6.52M+101.0% | 3.24M | |
| Current lease liability | 915K+391.9% | 186K-14.3% | 217K | |
| 39.0M+82.0% | 21.4M+47.6% | 14.5M | ||
| Long-term debt | 3.00M | 0.00 | — | |
| Non-current lease liability | 3.11M+5873.1% | 52.0K-78.7% | 244K | |
| Operating lease liability (total) | 4.02M+1589.5% | 238K | — | |
| Finance lease liability (total) | — | 0.00 | 0.00 | |
| Other non-current liabilities | 1.74M | 0.00 | — | |
| 753M+2.6% | 733M+695.8% | -123M | ||
| Common stock | 8.00K+0.0% | 8.00K | — | |
| Additional paid-in capital | 1.13B+18.9% | 951M+13804.6% | 6.84M | |
| Retained earnings | -379M-73.9% | -218M-67.8% | -130M | |
| Total liabilities & equity | 792M+4.9% | 755M+278.7% | 199M | |
| Common shares issued | 80.7M+6.0% | 76.2M+1358.3% | 5.22M | |
| Common shares outstanding | 80.7M+6.0% | 76.2M+1358.3% | 5.22M | |
| Shares outstanding (cover) | 84.4M+10.8% | 76.2M | — | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| -132M-68.1% | -78.7M-72.3% | -45.7M | ||
| Depreciation & amortization | 1.45M+4415.6% | 32.0K+88.2% | 17.0K | |
| Share-based compensation | 26.7M+134.0% | 11.4M+646.2% | 1.53M | |
| Deferred income taxes | -278K | — | — | |
| Change in receivables | 320K | — | — | |
| Change in inventory | 444K | — | — | |
| Change in payables | -1.64M-150.2% | 3.27M+62.8% | 2.01M | |
| -246M+18.3% | -301M-148.2% | -121M | ||
| Capital expenditure | 134K-42.7% | 234K | — | |
| Free cash flow | -132M-67.8% | -78.9M | — | |
| Acquisitions | 22.0M | 0.00 | 0.00 | |
| Purchases of investments | 1.07B+2.1% | 1.05B+102.1% | 518M | |
| Sales/maturities of investments | 844M+13.2% | 745M+88.0% | 396M | |
| 154M-75.6% | 628M+622.2% | 87.0M | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 147M-33.9% | 223M | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | |
| Net change in cash | -225M-190.3% | 249M+411.5% | -79.9M | |
| Interest paid | 103K | — | 376K | |
| Income taxes paid | 16.0K | — | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| Market cap | 3.51B+60.4% | 2.19B | — | |
| P/S | 867.8×-54.8% | 1919.1× | — | |
| P/B | 4.7×+56.3% | 3.0× | — | |
| Source filing | 10-K | 10-K | 10-K |
About this data
Source: CGON’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all CGON filings on SEC EDGAR → Not investment advice.